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Budd-Chiari syndrome is defined as hepatic venous outflow obstruction at any level from the small hepatic veins to the
junction of the inferior vena cava and the right atrium independent of the underlying disease. We report here a 40-year-
old male patient who complained of abdominal fullness and bilateral lower leg edema for 1 month. A physical examina-
tion disclosed bilateral lower leg edema. Abdominal sonography revealed a small amount of ascites with thrombosis of
the inferior vena cava and right hepatic vein. Viral hepatitis marker tests showed positive hepatitis B surface antigen.
Tumor markers showed elevated serum α-fetoprotein levels. Computed tomography and magnetic resonance imaging
confirmed hepatocellular carcinoma with inferior vena cava and right hepatic vein thrombosis. Therefore, hepatocellular
carcinoma with Budd-Chiari syndrome was diagnosed. The patient was treated with intravenous heparin, which was then
changed to oral warfarin. Although it is relatively rare, clinicians should be aware of hepatocellular carcinoma with Budd-
Chiari syndrome when leg edema occurs without hypoalbuminemia in patients with chronic hepatitis B, because these
patients are in the high-risk group for developing hepatocellular carcinoma. Regular follow-up of chronic hepatitis B,
including biochemical and sonography surveillance, should be performed. [J Chin Med Assoc 2010;73(2):93–96]
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Introduction
Budd-Chiari syndrome (BCS) was first described by
George Budd in 1845 as a classic triad of abdominal
pain, hepatomegaly and ascites.1 In 1899, Hans Chiari,
a pathologist, further documented the pathological
features of the disease.1 It is currently defined as hepatic
venous outflow obstruction at any level from the small
hepatic veins to the junction of the inferior vena cava
(IVC) and the right atrium independent of the under-
lying disease.2 We report here a case of hepatocellular
carcinoma (HCC) with the initial presentation of bilat-
eral lower leg edema and BCS.
Case Report
A 40-year-old male from Myanmar complained of
abdominal fullness and bilateral lower leg edema for 
1 month. He visited our outpatient department for fur-
ther evaluation. A physical examination disclosed bilat-
eral lower leg edema. The patient’s blood counts were
as follows: white blood cells were 8,300/mm3 (normal,
4,800–10,800/mm3), hemoglobin was 14.6 g/dL
(normal, 12–16 g/dL), and platelets were 215,000/
mm3 (normal, 130,000–400,000/mm3). Serum bio-
chemistry test results were as follows: alanine amino-
transferase levels were 216 IU/L (normal, 0–40 IU/L),
aspartate aminotransferase levels were 200 IU/L (nor-
mal, 5–45 IU/L), albumin levels were 3.9 g/dL (nor-
mal, 3.7–5.3 g/dL), total protein levels were 7.0 g/dL
(normal, 6.4–8.4 g/dL), and total bilirubin levels
were 1.8mg/dL (normal, 0.2–1.6mg/dL). Abdominal
ultrasound (Figure 1) showed the disappearance of
Doppler flow in the intrahepatic segment of the IVC
and the right hepatic vein. Therefore, the patient was
admitted for further evaluation.
After admission, 24-hour urine protein collection
showed only 0.567 g/day. The possibility of nephrotic
syndrome was unlikely. Abdominal computed tomog-
raphy revealed a hypoattenuated mass in hepatic seg-
ment 7 (S7) that measured 3.7 cm, adjacent to the
IVC. The mass had dense contrast enhancement in the
arterial phase and rapid washout in the portal venous
phase. There were contrast-filling defects within the
right hepatic vein (Figure 2A) and intrahepatic segment
of the IVC (Figure 2B), compatible with tumor throm-
bus. In addition, a wedge-shaped hypodense lesion was
found in hepatic S6 and S7, indicating liver infarction
due to thrombosis of the right hepatic vein. Abdominal
magnetic resonance imaging revealed a mass in hepatic
S7 that measured 4.4 cm. The lesion showed low
intensity on T1-weighted imaging (Figure 3A), high
intensity on T2-weighted imaging (Figure 3B), early
global contrast enhancement in the arterial phase
(Figure 3C), and rapid contrast washout in the portal
venous phase (Figure 3D). All of the imaging findings
confirmed HCC. Thrombosis in the intrahepatic seg-
ment of the IVC and right hepatic vein were also
observed, compatible with BCS.
Viral hepatitis marker tests showed positive hepa-
titis B surface antigen (HBsAg), but antibody against
hepatitis C virus was negative. Tumor markers showed
elevated α-fetoprotein levels of 31,158 ng/mL (nor-
mal, < 20 ng/mL), but carcinoembryonic antigen lev-
els were normal (2.39 ng/mL; normal, < 6 ng/mL).
Coagulation factors [protein C, 67% (normal, 80–
140%); protein S, 117% (normal, 60–130%)] were
within normal limits. Antiphospholipid antibody–
immunoglobulin G (IgG), cardiolipin–IgG, dissemi-
nated intravascular coagulation profile, paroxysmal
nocturnal hemoglobinuria marker and antinuclear
antibody were all negative.
Initially, the patient was treated with intravenous
heparin, which was then changed to oral warfarin.
Subsequently, we discussed the therapeutic modalities
including radiotherapy or target therapy with the
patient. However, he decided to receive traditional
herbal medicine and went back to Myanmar. There-
fore, we were unable to follow him up after the diag-
nosis was established. The final diagnosis was HCC
with BCS.
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Figure 1. Abdominal ultrasound shows the disappearance of
Doppler flow in the intrahepatic segment of the inferior vena cava
(arrowhead) and the right hepatic vein (arrow).
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Figure 2. Abdominal computed tomography shows contrast-filling defects within the (A) right hepatic vein (arrow) and (B) intrahepatic
segment of the inferior vena cava (arrow), compatible with tumor thrombus.
Discussion
HCC is the 5th most prevalent cancer in the world, caus-
ing 300,000–500,000 deaths per annum.3,4 In Taiwan,
it is the leading cause of cancer mortality in males and is
second in females.3 The common organs of metastasis
from HCC are lung, bone, brain, and adrenal glands.5
Although HCC with microscopic invasion is common
and occurs in 60–90% of patients with tumor size
>5cm,5,6 BCS is found in<1% of all HCC patients.7,8
The clinical manifestations for HCC with invasion to the
main vessels and BCS are diverse, from asymptomatic
status to abdominal pain, chest pain, dyspnea, hemateme-
sis, hemoptysis, anorexia, lower leg edema, and syn-
cope.7 Resection surgery, systemic chemotherapy, target
therapy with sorafenib, radiotherapy, and transcatheter
arterial chemoembolization have been reported as ther-
apeutic modalities for HCC patients with main portal
vein invasion or BCS.7–9 However, the long-term out-
come is quite dismal, with a median survival of approx-
imately 2–20 months in spite of therapy.7–9
In most cases, BCS can be diagnosed solely on 
the basis of imaging without liver biopsy.10 Doppler
ultrasonography of the liver has a sensitivity and speci-
ficity of 85–90% for the diagnosis of BCS.10 Bargallo
et al classified the ultrasound signs of BCS into 3 cate-
gories: specific signs (hepatic vein obstruction mani-
fested in different ways); suggestive signs (intrahepatic
venovenous, portovenous or portacaval collateral and
caudate vein > 3 mm in diameter); and nonspecific
signs (caudate lobe hypertrophy, extrahepatic collat-
erals, portal vein thrombosis, regeneration nodules,
inhomogeneous liver parenchyma, and ascites).11 Alter-
ations of the hepatic (71.1%) and/or caval (28.9%)
veins are the most frequent ultrasound signs of BCS,
and the combination of the 2 signs (97.8%) with cau-
date lobe hypertrophy (66.7%) exhibits the highest
positive predictive value for the diagnosis of BCS.10
Computed tomography scans further allow for the
detailed evaluation of patency of the hepatic vein and
IVC, as well as the degree of caudate lobe hypertro-
phy.1 In addition, magnetic resonance imaging may help
to differentiate chronic from acute disease and pro-
vide further delineation of vascular anatomy.1
The treatment modalities for BCS include treatment
of underlying disease, anticoagulation, percutaneous
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Figure 3. Abdominal magnetic resonance imaging demonstrates a hepatic mass in segment 7: (A) low intensity on T1-weighted 
imaging (arrow); (B) high intensity on T2-weighted imaging (arrow); (C) early global contrast enhancement in the arterial phase (arrow);
(D) rapid contrast washout in the portal venous phase (arrow).
angiography, transjugular intrahepatic portosystemic
shunt, and liver transplant.2 Early initiation of antico-
agulant therapy is recommended for all patients regard-
less of whether or not an underlying prothrombotic
disorder has been identified.12 However, a surprisingly
high incidence of heparin-induced thrombocytopenia
with unfractionated and low-molecular-weight heparin
has been reported.12 If the patient does not improve
with medical treatment, percutaneous angiography with
or without a stent should be considered. Transjugular
intrahepatic portosystemic shunt is an effective treat-
ment for patients with BCS uncontrolled by medical
therapy.13 In the 10–20% of patients in whom the thera-
pies mentioned above are unsuccessful, liver transplan-
tation is the remaining treatment option for BCS.14,15
Since recurrent BCS after transplantation has been
reported, life-long anticoagulation is recommended.16
Although the mortality rate of BCS at 3 years is as high
as 90% if untreated, excellent survival can be achieved
when prompt therapeutic procedures are performed.2,16
Nevertheless, if BCS is caused by HCC, the prognosis
is very poor in spite of aggressive therapies.
In our case, a 40-year-old male patient presented
with ascites and bilateral lower leg edema without pro-
teinuria and hypoalbuminemia. Nephrotic syndrome
and liver cirrhosis were unlikely candidates after an ini-
tial evaluation and, therefore, decreased venous return
of IVC was considered in the differential diagnosis.
Laboratory studies were carried out to exclude autoim-
mune and hematologic disorders. The patient had no
systemic prothrombotic risk factors of BCS such as
myeloproliferative diseases, antiphospholipid syndrome,
paroxysmal nocturnal hemoglobinuria, and Behcet’s
disease.2 Nevertheless, he had chronic hepatitis B,
which placed him in the high-risk group for developing
HCC. Alpha-fetoprotein levels were extremely high.
The imaging modalities, including dynamic com-
puted tomography and magnetic resonance imaging,
both demonstrated typical vascular characteristics to
establish a definite diagnosis of HCC. All the findings
mentioned above suggested that BCS in our patient
was secondary to HCC.
Although the combination is relatively rare, clini-
cians should be aware of HCC with BCS when leg
edema occurs without hypoalbuminemia in patients
with chronic hepatitis B, who are in the high-risk group
for developing HCC. More importantly, regular sur-
veillance by abdominal sonography is crucial for the
early detection of small HCC in high-risk patients. 
If small HCC can be detected early, the incidence of
vessel invasion and BCS would be diminished. Long-
term cancer-free survival could then be expected with
curative therapy modalities.
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